In the SW-620 tumor line, the CD44 subpopulation was increased following treatment with SC-1 (Figure 2B, n = 3, paired Student’s t test, p = 0.03, mean±s.e.m., control treated: 39.6±8.5% positive, SC-1 treated: 74.1±13.4% positive). The gene discussed is CD44; the disease is neoplasm.